Please provide your email address to receive an email when new articles are posted on . PCI was not cost-effective vs. optimal medical therapy alone in patients with CAD and HF. Intervention conferred ...

Please provide your email address to receive an email when new articles are posted on . For patients with vulnerable plaque but no flow-limiting stenosis, PCI provided better clinical outcomes than ...

The appropriate duration of dual antiplatelet therapy in patients at high risk for bleeding after the implantation of a drug-eluting coronary stent remains unclear. One month after they had undergone ...

Prasugrel monotherapy after percutaneous coronary intervention (PCI) with drug-eluting stents is not superior to dual-antiplatelet therapy (DAPT) for major bleeding but is non-inferior for ...

In the study, which entered people with both AF and recent acute coronary syndromes (ACS) or percutaneous coronary intervention (PCI), all of whom went on a P2Y12 inhibitor, such as clopidogrel, the ...

There has been a significant reduction in cardiac death and PCI-related outcomes, including stent thrombosis (ST), over 15 years, suggests a large, systematic review of randomized clinical trials.

Utilizing a magnetically-controlled capsule endoscopy system, the double-blind, randomized OPT-PEACE trial found that nearly all patients receiving antiplatelet therapy developed evidence of abnormal ...

Heart attack patients treated with primary percutaneous intervention (PCI) at hospitals after hours and on weekends wait longer to receive clot busters and other treatments and have a higher risk of ...

The efficacy of P2Y12 monotherapy depends on the type of drug used after discontinuation of dual antiplatelet therapy (DAPT) for post-PCI patients, according to a new patient-level meta-analysis.

The advent of thrombolytic therapy initiated the era of pharmacologic reperfusion in the acute phase of myocardial infarction (MI). Although it was a major improvement in the treatment of acute MI ...